200 related articles for article (PubMed ID: 35980831)
1. Prostate cancer cells demonstrate unique metabolism and substrate adaptability acutely after androgen deprivation therapy.
Filon MJ; Gillette AA; Yang B; Khemees TA; Skala MC; Jarrard DF
Prostate; 2022 Dec; 82(16):1547-1557. PubMed ID: 35980831
[TBL] [Abstract][Full Text] [Related]
2. CACNA1D overexpression and voltage-gated calcium channels in prostate cancer during androgen deprivation.
McKerr N; Mohd-Sarip A; Dorrian H; Breen C; A James J; McQuaid S; Mills IG; McCloskey KD
Sci Rep; 2023 Mar; 13(1):4683. PubMed ID: 36949059
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological inhibition of the Notch pathway enhances the efficacy of androgen deprivation therapy for prostate cancer.
Cui J; Wang Y; Dong B; Qin L; Wang C; Zhou P; Wang X; Xu H; Xue W; Fang YX; Gao WQ
Int J Cancer; 2018 Aug; 143(3):645-656. PubMed ID: 29488214
[TBL] [Abstract][Full Text] [Related]
4. Somatostatin derivative (smsDX) targets cellular metabolism in prostate cancer cells after androgen deprivation therapy.
Yan L; Xing Z; Guo Z; Fang Z; Jiao W; Guo X; Xu Z; Fang Z; Liu Z
PLoS One; 2013; 8(2):e55790. PubMed ID: 23409045
[TBL] [Abstract][Full Text] [Related]
5. Stimulation of cellular senescent processes, including secretory phenotypes and anti-oxidant responses, after androgen deprivation therapy in human prostate cancer.
Kawata H; Kamiakito T; Nakaya T; Komatsubara M; Komatsu K; Morita T; Nagao Y; Tanaka A
J Steroid Biochem Mol Biol; 2017 Jan; 165(Pt B):219-227. PubMed ID: 27329245
[TBL] [Abstract][Full Text] [Related]
6. Intermittent androgen deprivation therapy in advanced prostate cancer.
Alva A; Hussain M
Curr Treat Options Oncol; 2014 Mar; 15(1):127-36. PubMed ID: 24395278
[TBL] [Abstract][Full Text] [Related]
7. Preclinical efficacy of growth hormone-releasing hormone antagonists for androgen-dependent and castration-resistant human prostate cancer.
Fahrenholtz CD; Rick FG; Garcia MI; Zarandi M; Cai RZ; Block NL; Schally AV; Burnstein KL
Proc Natl Acad Sci U S A; 2014 Jan; 111(3):1084-9. PubMed ID: 24395797
[TBL] [Abstract][Full Text] [Related]
8. A carbon 21 steroidal metabolite from progestin, 20β-hydroxy-5α-dihydroprogesterone, stimulates the androgen receptor in prostate cancer cells.
Ando T; Nishiyama T; Takizawa I; Miyashiro Y; Hara N; Tomita Y
Prostate; 2018 Feb; 78(3):222-232. PubMed ID: 29194690
[TBL] [Abstract][Full Text] [Related]
9. CaV1.3 enhanced store operated calcium promotes resistance to androgen deprivation in prostate cancer.
O'Reilly D; Downing T; Kouba S; Potier-Cartereau M; McKenna DJ; Vandier C; Buchanan PJ
Cell Calcium; 2022 May; 103():102554. PubMed ID: 35193095
[TBL] [Abstract][Full Text] [Related]
10. Hypoxia-independent downregulation of hypoxia-inducible factor 1 targets by androgen deprivation therapy in prostate cancer.
Ragnum HB; Røe K; Holm R; Vlatkovic L; Nesland JM; Aarnes EK; Ree AH; Flatmark K; Seierstad T; Lilleby W; Lyng H
Int J Radiat Oncol Biol Phys; 2013 Nov; 87(4):753-60. PubMed ID: 24035332
[TBL] [Abstract][Full Text] [Related]
11. Crosstalk Between Androgen-sensitive and Androgen-insensitive Prostate Cancer Cells.
Takezawa Y; Izumi K; Machioka K; Iwamoto H; Naito R; Makino T; Kadomoto S; Natsagdorj A; Kadono Y; Keller ET; Zhang J; Mizokami A
Anticancer Res; 2018 Apr; 38(4):2045-2055. PubMed ID: 29599322
[TBL] [Abstract][Full Text] [Related]
12. Androgen Deprivation Therapy Potentiates the Efficacy of Vascular Targeted Photodynamic Therapy of Prostate Cancer Xenografts.
Kim K; Watson PA; Lebdai S; Jebiwott S; Somma AJ; La Rosa S; Mehta D; Murray KS; Lilja H; Ulmert D; Monette S; Scherz A; Coleman JA
Clin Cancer Res; 2018 May; 24(10):2408-2416. PubMed ID: 29463549
[No Abstract] [Full Text] [Related]
13. AT-101 (R-(-)-gossypol acetic acid) enhances the effectiveness of androgen deprivation therapy in the VCaP prostate cancer model.
McGregor N; Patel L; Craig M; Weidner S; Wang S; Pienta KJ
J Cell Biochem; 2010 Aug; 110(5):1187-94. PubMed ID: 20589722
[TBL] [Abstract][Full Text] [Related]
14. Serum-free complete medium, an alternative medium to mimic androgen deprivation in human prostate cancer cell line models.
Fiandalo MV; Wilton JH; Mantione KM; Wrzosek C; Attwood KM; Wu Y; Mohler JL
Prostate; 2018 Feb; 78(3):213-221. PubMed ID: 29194687
[TBL] [Abstract][Full Text] [Related]
15. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
[TBL] [Abstract][Full Text] [Related]
16. Targeting the androgen receptor signaling pathway in advanced prostate cancer.
Chung C; Abboud K
Am J Health Syst Pharm; 2022 Jul; 79(15):1224-1235. PubMed ID: 35390118
[TBL] [Abstract][Full Text] [Related]
17. The influence of low-carbohydrate diets on the metabolic response to androgen-deprivation therapy in prostate cancer.
Chi JT; Lin PH; Tolstikov V; Oyekunle T; Alvarado GCG; Ramirez-Torres A; Chen EY; Bussberg V; Chi B; Greenwood B; Sarangarajan R; Narain NR; Kiebish MA; Freedland SJ
Prostate; 2021 Jul; 81(10):618-628. PubMed ID: 33949711
[TBL] [Abstract][Full Text] [Related]
18. Effects of vitamin D as a regulator of androgen intracrinology in LNCAP prostate cancer cells.
Smith KW; Thompson PD; Rodriguez EP; Mackay L; Cobice DF
Biochem Biophys Res Commun; 2019 Nov; 519(3):579-584. PubMed ID: 31537382
[TBL] [Abstract][Full Text] [Related]
19. Androgen deprivation modulates gene expression profile along prostate cancer progression.
Volante M; Tota D; Giorcelli J; Bollito E; Napoli F; Vatrano S; Buttigliero C; Molinaro L; Gontero P; Porpiglia F; Tucci M; Papotti M; Berruti A; Rapa I
Hum Pathol; 2016 Oct; 56():81-8. PubMed ID: 27342909
[TBL] [Abstract][Full Text] [Related]
20. Androgens modify therapeutic response to cabazitaxel in models of advanced prostate cancer.
Begemann D; Wang Y; Yang W; Kyprianou N
Prostate; 2020 Sep; 80(12):926-937. PubMed ID: 32542812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
